Guerbet S.A.

Guerbet is a French pharmaceutical group that develops, markets, and provides maintenance services for medical equipment and devices destined for diagnostic and interventional imaging. Co.'s portfolio comprises media solutions covering MRI, X-rays and products devoted to International Radiology and Theranostics and medical devices. Co. organizes its operation by product family covering Magnetic Resonance Imaging (MRI), X-rays (XR) and Interventional Radiology and Theranostics (IRT). The MRI family includes Dotarem® and Artirem®; Co.'s X-ray product family includes Xenetix®, Optiray®/Optiject®, Oxilan®, and Telebrix®; and the IRT product family has Lipiodol®, Bleu Patente V and Hexabrix®.
  • TickerGBT
  • ISINFR0000032526
  • ExchangeEuronext Paris
  • SectorPharmaceuticals & Biotechnology
  • CountryFrance

Analysts

GUERBET sees a downgrade to Neutral on account of less fundamental stars

The independent financial analyst theScreener just lowered the general evaluation of GUERBET (FR), active in the Pharmaceuticals industry. As regards its fundamental valuation, the title now shows 1 out of 4 stars while market behaviour can be considered moderately risky. theScreener believes that the title remains under pressure due to the loss of a star(s) and downgrades its general evaluation to Neutral. As of the analysis date December 20, 2019, the closing price was EUR 43.70 and its target price was estimated at EUR 41.52.

Christophe-Raphaël Ganet

Guerbet : Unexpected replacement of the CEO - 2023 guidance suspended - Downward revision to our estimates, target price and recommendation

>Yves L’Epine, CEO since 2011, replaced – Road map adjusted - In a press release issued yesterday evening, we learned that Guerbet’s board of directors:i/ has appointed David Hale to the post of CEO as of 1 January 2020, replacing Yves L’Epine (CEO since end-2011); ii/ confirmed the group’s strategic ambition - expressed via the GEAR 2023 plan with development in the interventional radiology and digital segments - but indicated that an updated plan would be ...

Christophe-Raphaël Ganet

Guerbet : Remplacement (surprise) du CEO – Guidances 2023 suspendues – Abaissement de nos estimations, de notre OC et de notre recommandation

>Yves l’Epine, CEO depuis 2011, est remplacé – Feuille de route ajustée - Dans un communiqué paru hier soir, on apprend que le Conseil d’administration de Guerbet:i/ a nommé David Hale poste de Directeur général à compter du 1er janvier 2020, en remplacement de Yves L’Epine (CEO depuis fin 2011), ii/ confirme l’ambition stratégique du groupe -exprimée au travers du plan GEAR 2023 avec le développement sur les segments de l’imagerie interventionnelle et du di...

Feasibility Study Results in December to be a Catalyst for this Junior

Feasibility Study Results in December to be a Catalyst for this Junior